Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.
about
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.Progress toward active or passive HIV-1 vaccination.How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.Fight fire with fire: Gene therapy strategies to cure HIV.Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.Env-Specific Antibodies in Chronic Infection versus in Vaccination.Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor.Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children.Prospects for passive immunity to prevent HIV infection.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells.Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.eCD4-Ig variants that more potently neutralize HIV-1.Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses.Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection.Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known EpitopesDiverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodiesStructural Insights from HIV-Antibody Coevolution and Related Immunization StudiesThe human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogenIdentification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donorHIV Entry and Its Inhibition by Bifunctional Antiviral ProteinsAntibodies and Antibody Derivatives: New Partners in HIV Eradication StrategiesEngineering multi-specific antibodies against HIV-1
P2860
Q30490945-CB8C6DD9-4680-40F7-9F1A-4E390B054839Q34550046-1B8DF8F3-F855-4137-A97E-2E236EDB4697Q36303368-F660238F-4378-4168-833F-997572BA0422Q36319309-5CFE03F4-7B34-4D12-A1B0-6D96FC59FE69Q37549777-AB63C109-86B5-4374-8D39-3DC7755FC669Q39250593-C2831921-49C0-4129-A92E-EBBCC6A1D169Q39425614-0FFE3C9C-48EE-4E6D-B29C-E8A9858C5571Q40076760-14525419-ED7A-436A-8930-9FBDE02ACE3EQ40118226-873935A7-2279-4F15-BC3C-AC4E3C7D746FQ40187584-4266FEC8-D55D-4267-B3D8-09D51119C74FQ40198060-E9019905-31D4-4741-B4D7-12E2F1A1E43FQ41475637-DB165881-A5EF-4D5C-ABFD-62A65262E9D2Q42362648-20542226-A7ED-49C9-B2AF-599E028F2B26Q44536209-9AD5B1EE-2CC8-40F8-A167-BBB34DB8CD82Q45333913-FAA7F9F2-42FF-44E1-8EE3-4A0033E32B9FQ46621371-72610A14-43D1-4F06-B0D8-5D123EF9495FQ47110966-69C1DED5-F5F2-4F09-9D76-0D1BE26B08C5Q47232975-EA864B91-E5F3-4DD5-8B4B-C692CB0CC0C5Q47547402-AE9A6A1F-88B9-43D9-9A48-452186E61274Q47548101-A4D8ED29-E457-45E5-BFC7-22590052FD19Q47566038-A0FD5708-AC46-4A92-98BE-1A9064259F4CQ49997190-FCB86248-66CC-47CE-AD08-F23C4A8CF619Q50420466-6B9D4764-DBB9-48DF-9A56-003C07F08C3AQ52624996-F8ABD155-536D-4334-8BE8-681387C8AE93Q52626499-84AF509A-FE19-4CBD-A9DC-D74F510D5910Q52673965-BF577543-E394-4DD5-8964-80330D391F78Q53081267-1414A54A-1653-4DD7-B29E-70AC1EBD6976Q53689028-DB1DAB4C-9102-4402-9A60-4E12C46ED598Q54230395-316D1771-3BFD-4325-9F4B-E92C1F355573Q55347049-1E5FB62D-4DE0-4A22-9DE0-9B029349AF3AQ55359818-0E91582D-8E63-425C-B469-C624D39A2C03Q55436995-8DB84874-AEEB-4E30-A0E5-27107F63677BQ56913214-B103EDD4-E517-49E3-9C96-179DA277679AQ57003103-33645F42-E7A5-4BFE-A632-A77486EDF131Q57093739-444809EE-440D-4EAF-8378-4E759BFFBF72Q57094341-427F8BC2-717A-4109-8FEB-A9E0CC06B8ACQ58079900-3C79A734-73E0-4B27-BFC5-8FD3CDAB5D5CQ58555325-C5F6FF5C-877C-4DE6-931B-9A55C1251F61Q58572618-63A8115A-DCFC-44AA-90F0-A543194CCDFAQ58696428-8FFC241E-FAB9-403E-B708-15C0FCC6D2A7
P2860
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Identification of a CD4-Bindin ...... ar-Pan Neutralization Breadth.
@en
type
label
Identification of a CD4-Bindin ...... ar-Pan Neutralization Breadth.
@en
prefLabel
Identification of a CD4-Bindin ...... ar-Pan Neutralization Breadth.
@en
P2093
P2860
P50
P1433
P1476
Identification of a CD4-Bindin ...... ar-Pan Neutralization Breadth.
@en
P2093
Aliaksandr Druz
Amy Ransier
Anqi Zheng
Baoshan Zhang
Byong H Kang
Chaim A Schramm
Daniel C Douek
Gwo-Yu Chuang
Ivelin S Georgiev
P2860
P304
P356
10.1016/J.IMMUNI.2016.10.027
P407
P577
2016-11-01T00:00:00Z